Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

2017 ESMO Congress
Tweet this page

Toni K. Choueiri, MD, of Dana-Farber Cancer Institute, discusses updated overall survival results on cabozantinib vs sunitinib as initial targeted treatment for patients with metastatic renal cell carcinoma (Abstract LBA38).

Sep

Today In Oncology

Olaparib Receives Positive pCODR Recommendation for Treatment of BRCA-Mutated Ovarian Cancer

Durvalumab Consolidation After Chemoradiotherapy in Stage III NSCLC

Toni K. Choueiri, MD, on RCC: Results From the CABOSUN Trial

Olaparib Receives Positive pCODR Recommendation for Treatment of BRCA-Mutated Ovarian Cancer

Durvalumab Consolidation After Chemoradiotherapy in Stage III NSCLC

Adjuvant Nivolumab vs Ipilimumab in Resected Stage III or IV Melanoma

Preexisting Dementia and Survival in Older Patients With Stage III Colon Cancer

Tibetan Yoga Practice May Improve Sleep Quality for Patients With Breast Cancer Undergoing Chemotherapy

Positive Results from Phase III MURANO Trial Evaluating Venetoclax in Combination With Rituximab in Relapsed/Refractory CLL

Overall Survival With Nivolumab/Ipilimumab, or Nivolumab Alone, vs Ipilimumab in Advanced Melanoma

Surgeon-Initiated Gene-Expression Profile Testing in Early-Stage Breast Cancer and Time to Start of Chemotherapy